Show simple item record

dc.contributor.authorParaboschi, I
dc.contributor.authorTurnock, S
dc.contributor.authorKramer-Marek, G
dc.contributor.authorMusleh, L
dc.contributor.authorBarisa, M
dc.contributor.authorAnderson, J
dc.contributor.authorGiuliani, S
dc.date.accessioned2021-06-11T12:58:20Z
dc.date.available2021-06-11T12:58:20Z
dc.identifier.citationCritical reviews in oncology/hematology, 2021, 161 pp. 103325 - ?
dc.identifier.issn1040-8428
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4631
dc.identifier.eissn1879-0461
dc.identifier.doi10.1016/j.critrevonc.2021.103325
dc.description.abstractNear-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen.
dc.formatPrint-Electronic
dc.format.extent103325 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPhotosensitizing Agents
dc.subjectAntibodies, Monoclonal
dc.subjectImmunoconjugates
dc.subjectImmunotherapy
dc.subjectPhototherapy
dc.titleNear-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications.
dc.typeJournal Article
dcterms.dateAccepted2021-03-26
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.critrevonc.2021.103325
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCritical reviews in oncology/hematology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.publication-statusPublished
pubs.volume161
pubs.embargo.termsNot known
icr.researchteamPreclinical Molecular Imaging
icr.researchteamPreclinical Molecular Imagingen_US
dc.contributor.icrauthorKramer-Marek, Gabrielaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0